| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
|
N Engl J Med
|
2004
|
7.04
|
|
2
|
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
|
J Clin Invest
|
2008
|
3.89
|
|
3
|
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
|
J Clin Oncol
|
2007
|
3.23
|
|
4
|
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells.
|
Blood
|
2008
|
3.19
|
|
5
|
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
|
J Clin Oncol
|
2005
|
3.05
|
|
6
|
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.
|
Blood
|
2010
|
2.72
|
|
7
|
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
|
Blood
|
2008
|
2.72
|
|
8
|
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.
|
Blood
|
2012
|
2.37
|
|
9
|
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
|
J Clin Oncol
|
2011
|
2.26
|
|
10
|
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.
|
J Clin Invest
|
2005
|
2.15
|
|
11
|
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic.
|
Br J Haematol
|
2013
|
2.06
|
|
12
|
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.
|
Blood
|
2004
|
2.01
|
|
13
|
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
|
J Clin Oncol
|
2002
|
1.98
|
|
14
|
FLT3 mutations in childhood acute lymphoblastic leukemia.
|
Blood
|
2003
|
1.91
|
|
15
|
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
|
Blood
|
2008
|
1.90
|
|
16
|
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
|
Clin Infect Dis
|
2006
|
1.78
|
|
17
|
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.
|
J Clin Oncol
|
2006
|
1.68
|
|
18
|
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
|
Cancer Res
|
2009
|
1.65
|
|
19
|
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.
|
J Clin Oncol
|
2013
|
1.63
|
|
20
|
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.
|
J Clin Oncol
|
2007
|
1.62
|
|
21
|
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies.
|
Blood
|
2013
|
1.62
|
|
22
|
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
|
Proc Natl Acad Sci U S A
|
2009
|
1.61
|
|
23
|
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
|
Blood
|
2013
|
1.61
|
|
24
|
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
|
Blood
|
2012
|
1.60
|
|
25
|
SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma.
|
Blood
|
2011
|
1.57
|
|
26
|
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2012
|
1.56
|
|
27
|
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
|
J Clin Oncol
|
2012
|
1.55
|
|
28
|
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.
|
Blood
|
2007
|
1.53
|
|
29
|
The role of B7 family molecules in hematologic malignancy.
|
Blood
|
2012
|
1.47
|
|
30
|
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.
|
Blood
|
2009
|
1.45
|
|
31
|
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia.
|
Leuk Res
|
2008
|
1.42
|
|
32
|
Risk categories and refractory CLL in the era of chemoimmunotherapy.
|
Blood
|
2012
|
1.41
|
|
33
|
Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.
|
Cancer
|
2010
|
1.40
|
|
34
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
35
|
Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.
|
Blood
|
2003
|
1.33
|
|
36
|
Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
|
Gastroenterology
|
2013
|
1.32
|
|
37
|
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.
|
Blood
|
2002
|
1.31
|
|
38
|
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
|
Blood
|
2008
|
1.27
|
|
39
|
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.
|
Blood
|
2009
|
1.26
|
|
40
|
Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.
|
Blood
|
2009
|
1.24
|
|
41
|
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.
|
Blood
|
2007
|
1.21
|
|
42
|
Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.
|
Proc Natl Acad Sci U S A
|
2013
|
1.17
|
|
43
|
EZH2 mutations are frequent and represent an early event in follicular lymphoma.
|
Blood
|
2013
|
1.17
|
|
44
|
Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
|
PLoS One
|
2012
|
1.16
|
|
45
|
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.
|
Blood
|
2014
|
1.15
|
|
46
|
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.
|
Clin Cancer Res
|
2013
|
1.12
|
|
47
|
T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.
|
Blood
|
2002
|
1.12
|
|
48
|
Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment.
|
Blood
|
2010
|
1.12
|
|
49
|
Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
|
J Clin Oncol
|
2012
|
1.09
|
|
50
|
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
|
Br J Haematol
|
2002
|
1.09
|
|
51
|
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.
|
Blood
|
2008
|
1.07
|
|
52
|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
1.03
|
|
53
|
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.
|
Biol Blood Marrow Transplant
|
2007
|
1.02
|
|
54
|
Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.
|
Blood
|
2013
|
1.02
|
|
55
|
Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia.
|
Blood
|
2014
|
1.01
|
|
56
|
Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications.
|
Hematol Oncol Clin North Am
|
2013
|
1.01
|
|
57
|
Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells.
|
Blood
|
2007
|
1.01
|
|
58
|
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.
|
Blood
|
2008
|
1.00
|
|
59
|
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
|
J Clin Oncol
|
2014
|
0.99
|
|
60
|
Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia.
|
Br J Haematol
|
2005
|
0.99
|
|
61
|
Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution.
|
Transfusion
|
2003
|
0.98
|
|
62
|
Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells.
|
Blood
|
2004
|
0.97
|
|
63
|
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.
|
Haematologica
|
2009
|
0.96
|
|
64
|
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
|
Leuk Lymphoma
|
2012
|
0.96
|
|
65
|
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.
|
Blood
|
2010
|
0.95
|
|
66
|
Cutaneous cryptococcosis in Hodgkin lymphoma.
|
Br J Haematol
|
2013
|
0.94
|
|
67
|
The role of the tumor microenvironment in hematological malignancies and implication for therapy.
|
Front Biosci
|
2005
|
0.93
|
|
68
|
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.
|
Blood
|
2007
|
0.93
|
|
69
|
Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.
|
J Immunother
|
2010
|
0.93
|
|
70
|
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.93
|
|
71
|
The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
|
Br J Haematol
|
2010
|
0.92
|
|
72
|
Stem cell transplantation for non-Hodgkin's lymphoma.
|
Hematol Oncol Clin North Am
|
2008
|
0.91
|
|
73
|
Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease.
|
J Clin Oncol
|
2006
|
0.90
|
|
74
|
Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis.
|
Blood
|
2004
|
0.90
|
|
75
|
T-cell function in chronic lymphocytic leukaemia.
|
Semin Cancer Biol
|
2010
|
0.90
|
|
76
|
Differential and tumor-specific expression of CD160 in B-cell malignancies.
|
Blood
|
2011
|
0.89
|
|
77
|
Development of original donor cell leukemia after successful engraftment from a second donor.
|
Blood
|
2007
|
0.88
|
|
78
|
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.88
|
|
79
|
Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
|
Exp Hematol
|
2002
|
0.88
|
|
80
|
CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.
|
Blood
|
2010
|
0.87
|
|
81
|
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.
|
Blood
|
2011
|
0.87
|
|
82
|
Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia.
|
Blood
|
2007
|
0.87
|
|
83
|
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.
|
Exp Hematol
|
2002
|
0.85
|
|
84
|
Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis.
|
Leuk Res
|
2003
|
0.84
|
|
85
|
Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma.
|
J Clin Oncol
|
2011
|
0.84
|
|
86
|
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
|
Leuk Res
|
2004
|
0.83
|
|
87
|
Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.
|
Blood
|
2006
|
0.83
|
|
88
|
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups.
|
Histopathology
|
2013
|
0.82
|
|
89
|
Chronic lymphocytic leukemia: an historical perspective.
|
Hematology Am Soc Hematol Educ Program
|
2008
|
0.81
|
|
90
|
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.
|
Blood
|
2004
|
0.81
|
|
91
|
Vaccine therapy and chronic lymphocytic leukaemia.
|
Best Pract Res Clin Haematol
|
2008
|
0.81
|
|
92
|
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.
|
Transfusion
|
2004
|
0.80
|
|
93
|
Chronic lymphocytic leukemia: an update on biology and treatment.
|
Curr Oncol Rep
|
2011
|
0.80
|
|
94
|
Transplantation in chronic lymphocytic leukemia: timing and expectations.
|
Clin Lymphoma Myeloma
|
2009
|
0.80
|
|
95
|
Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis.
|
Br J Haematol
|
2012
|
0.80
|
|
96
|
Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity.
|
Curr Pharm Des
|
2003
|
0.80
|
|
97
|
Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia.
|
Proc Natl Acad Sci U S A
|
2012
|
0.80
|
|
98
|
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
|
Curr Pharm Des
|
2012
|
0.80
|
|
99
|
Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens.
|
J Immunol Methods
|
2009
|
0.79
|
|
100
|
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2004
|
0.79
|
|
101
|
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.
|
Br J Haematol
|
2012
|
0.78
|
|
102
|
Immune reconstitution in chronic lymphocytic leukemia.
|
Curr Hematol Malig Rep
|
2012
|
0.78
|
|
103
|
Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.
|
Br J Haematol
|
2013
|
0.78
|
|
104
|
Role of autologous stem cell transplantation in chronic lymphocytic leukemia.
|
Curr Opin Hematol
|
2003
|
0.78
|
|
105
|
Autografting CLL: the game is over!
|
Blood
|
2011
|
0.78
|
|
106
|
Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract.
|
Br J Haematol
|
2012
|
0.77
|
|
107
|
Role of allogeneic hematopoietic stem-cell transplantation in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2008
|
0.77
|
|
108
|
Stem cell transplantation in chronic lymphocytic leukaemia - steering a safe course over shifting sands.
|
Best Pract Res Clin Haematol
|
2010
|
0.77
|
|
109
|
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
|
PLoS One
|
2012
|
0.77
|
|
110
|
The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.
|
Hematology
|
2008
|
0.77
|
|
111
|
Dangerous power: mitochondria in CLL cells.
|
Blood
|
2014
|
0.77
|
|
112
|
Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone.
|
Eur J Haematol
|
2014
|
0.76
|
|
113
|
Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia.
|
Discov Med
|
2013
|
0.76
|
|
114
|
Blockade of chemotaxis in graft-versus-host disease.
|
N Engl J Med
|
2012
|
0.76
|
|
115
|
Lymphoid neoplasia. Laser-capturing the essence of Hodgkin lymphoma.
|
Blood
|
2012
|
0.76
|
|
116
|
The kiss of death in FL.
|
Blood
|
2011
|
0.76
|
|
117
|
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
|
Haematologica
|
2012
|
0.76
|
|
118
|
Interesting times in the diagnosis and treatment of CLL.
|
Oncology (Williston Park)
|
2009
|
0.75
|
|
119
|
Less expensive CARs?
|
Cytotherapy
|
2012
|
0.75
|
|
120
|
Hanging tough: CMV-specific CD8+ T cells in CLL.
|
Blood
|
2014
|
0.75
|
|
121
|
Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma - response to Meissner et al.
|
Br J Haematol
|
2014
|
0.75
|
|
122
|
Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients.
|
Oncology (Williston Park)
|
2012
|
0.75
|
|
123
|
Stem cell mimicry: key to transformation?
|
Blood
|
2009
|
0.75
|
|
124
|
A shot in the arm for radiotherapy.
|
Blood
|
2013
|
0.75
|
|
125
|
The 3 Rs in CLL immune dysfunction.
|
Blood
|
2010
|
0.75
|
|
126
|
Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.
|
Nat Genet
|
2016
|
0.75
|
|
127
|
Transplantation in chronic lymphocytic leukemia.
|
Curr Hematol Malig Rep
|
2007
|
0.75
|
|
128
|
Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias.
|
Br J Haematol
|
2005
|
0.75
|
|
129
|
Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.
|
Biol Blood Marrow Transplant
|
2002
|
0.75
|
|
130
|
Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients.
|
Expert Opin Med Diagn
|
2008
|
0.75
|
|
131
|
Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation.
|
Methods Mol Med
|
2005
|
0.75
|